Early reads from the American Association for the Study of Liver Diseases (AASLD) Boston conference indicates a tight race to treat the genotype 1 form of hepatitis C. The outlook is that Gilead and ...
Bashar A. Aqel, MD, Mayo Clinic, Phoenix, Arizona, presented results from phase 2 of the COSMOS (Combination Of SiMeprevir and sOfosbuvir in hepatitis C virus genotype 1 infected patients) trial. On ...
Hepatitis C’s second wave has crested and crashed, and this gold rush looks like it will be succeeded by a new generation of more effective, if less lucrative agents. Predictably, Gilead Sciences ...
HealthDay News — The FDA has approved a new test to help healthcare providers identify the genotype of a person’s hepatitis C infection. The Abbott RealTime HCV ...
Mavyret is intended to treat adults with all types of chronic hepatitis C virus with mild or no cirrhosis who have not previously received treatment for the illness. Patients with moderate to severe ...
While the cost of novel hepatitis C drugs has been rigorously debated, real-world data on the safety and efficacy of these drugs has now started showing up. A white paper released by CVS Health ...
New medications called direct-acting antivirals (DAAs) have transformed the treatment of hepatitis C. Twelve weeks on one of these drugs cures the infection in 95 percent or more of people who take it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback